Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) PT at $14.25

Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) have earned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $11.75.

Several analysts recently weighed in on the stock. Wells Fargo & Company reissued an “equal weight” rating and issued a $4.00 price objective on shares of Inozyme Pharma in a research note on Friday. Raymond James reduced their price objective on shares of Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Inozyme Pharma in a research note on Thursday, April 10th. Wedbush cut shares of Inozyme Pharma from a “strong-buy” rating to a “hold” rating in a research note on Friday. Finally, Needham & Company LLC cut shares of Inozyme Pharma from a “moderate buy” rating to a “hold” rating in a research note on Friday.

Inozyme Pharma Trading Up 1.0%

Shares of INZY stock opened at $3.99 on Thursday. The firm has a 50 day moving average price of $1.15 and a two-hundred day moving average price of $1.85. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $257.60 million, a PE ratio of -2.56 and a beta of 1.35. Inozyme Pharma has a 12-month low of $0.72 and a 12-month high of $6.24.

Inozyme Pharma (NASDAQ:INZY) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). As a group, analysts predict that Inozyme Pharma will post -1.59 earnings per share for the current year.

Institutional Trading of Inozyme Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Harvest Investment Services LLC bought a new position in shares of Inozyme Pharma in the fourth quarter worth approximately $31,000. Graham Capital Management L.P. bought a new position in shares of Inozyme Pharma in the fourth quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Inozyme Pharma in the fourth quarter worth approximately $38,000. ProShare Advisors LLC bought a new position in shares of Inozyme Pharma in the fourth quarter worth approximately $49,000. Finally, D. E. Shaw & Co. Inc. bought a new position in shares of Inozyme Pharma in the fourth quarter worth approximately $49,000. 88.30% of the stock is owned by hedge funds and other institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.